Overview

China Oncology Drugs Market is poised to value over USD 13.2 billion by 2027 end at a CAGR of over 8.6% during the forecast period 2020 to 2027.

FutureWise Market Research has instantiated a report that provides an intricate analysis of China Oncology Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the China Oncology Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the China Oncology Drugs Market:
• AbbVie Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Celgene Corporation
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Shanghai Junshi Biosciences Co., Ltd.
• Beigene
• Jiangsu Hengrui Medicine Co., Ltd.
• Pfizer Inc.
• GlaxoSmithKline plc
(Note: The list of the major players will be updated with the latest market scenario and trends)

China Oncology Drugs Market Segmentation:
By Drug Class Type
• Chemotherapy
• Targeted Therapy
• Immunotherapy Therapy
• Hormonal Therapy
By Indication
• Blood Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Prostate Cancer
• Lung Cancer
• Skin Cancer
• Ovarian Cancer
• Cervical Cancer  
• Kidney Cancer
• Other Cancers

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the China Oncology Drugs Market By Drug Class Type and By Indication.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— China
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. China Oncology Drugs Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of China Oncology Drugs Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. China Oncology Drugs Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. China Oncology Drugs Market, By Drug Class Type Historical Analysis and Forecast 2020-2027 (USD Million)
  7.1. Chemotherapy
  7.2. Targeted Therapy
  7.3. Immunotherapy Therapy
  7.4. Hormonal Therapy

8. China Oncology Drugs Market, By Indication Historical Analysis and Forecast 2020-2027 (USD Million)
  8.1. Blood Cancer
  8.2. Breast Cancer
  8.3. Gastrointestinal Cancer
  8.4. Prostate Cancer
  8.5. Lung Cancer
  8.6. Skin Cancer
  8.7. Ovarian Cancer
  8.8. Cervical Cancer  
  8.9. Kidney Cancer
  8.10. Other Cancers

9. Market Share Analysis and Competitive Landscape  
   9.1. China Landscape - Key Players, Revenue and Presence
   9.2. China Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   9.3. China Emerging Companies
   9.4. China - Market Share Analysis and Key Regional Players
   9.5. China Key Player - Growth Matrix

10. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   10.1. AbbVie Inc.
         10.1.1. Company Overview
         10.1.2. Product Portfolio
         10.1.3. SWOT Analysis
         10.1.4. Financial Overview
         10.1.5. Strategic Overview
   10.2. Astellas Pharma Inc.
         10.2.1. Company Overview
         10.2.2. Product Portfolio
         10.2.3. SWOT Analysis
         10.2.4. Financial Overview
         10.2.5. Strategic Overview
   10.3. AstraZeneca PLC
         10.3.1. Company Overview
         10.3.2. Product Portfolio
         10.3.3. SWOT Analysis
         10.3.4. Financial Overview
         10.3.5. Strategic Overview
   10.4. Bristol-Myers Squibb Company
         10.4.1. Company Overview
         10.4.2. Product Portfolio
         10.4.3. SWOT Analysis
         10.4.4. Financial Overview
         10.4.5. Strategic Overview
   10.5. Celgene Corporation
         10.5.1. Company Overview
         10.5.2. Product Portfolio
         10.5.3. SWOT Analysis
         10.5.4. Financial Overview
         10.5.5. Strategic Overview          
   10.6. F. Hoffmann-La Roche Ltd.
         10.6.1. Company Overview
         10.6.2. Product Portfolio
         10.6.3. SWOT Analysis
         10.6.4. Financial Overview
         10.6.5. Strategic Overview      
   10.7. Johnson & Johnson
         10.7.1. Company Overview
         10.7.2. Product Portfolio
         10.7.3. SWOT Analysis
         10.7.4. Financial Overview
         10.7.5. Strategic Overview
   10.8. Shanghai Junshi Biosciences Co., Ltd.
         10.8.1. Company Overview
         10.8.2. Product Portfolio
         10.8.3. SWOT Analysis
         10.8.4. Financial Overview
         10.8.5. Strategic Overview
   10.9. Beigene
         10.9.1. Company Overview
         10.9.2. Product Portfolio
         10.9.3. SWOT Analysis
         10.9.4. Financial Overview
         10.9.5. Strategic Overview
   10.10.Jiangsu Hengrui Medicine Co., Ltd.
         10.10.1. Company Overview
         10.10.2. Product Portfolio
         10.10.3. SWOT Analysis
         10.10.4. Financial Overview
         10.10.5. Strategic Overview
   10.11. Pfizer Inc.
         10.11.1. Company Overview
         10.11.2. Product Portfolio
         10.11.3. SWOT Analysis
         10.11.4. Financial Overview
         10.11.5. Strategic Overview
   10.12.GlaxoSmithKline plc
         10.12.1. Company Overview
         10.12.2. Product Portfolio
         10.12.3. SWOT Analysis
         10.12.4. Financial Overview
         10.12.5. Strategic Overview

16. Pre and Post COVID-19 Impact
   16.1. Positive influence on the healthcare industry
   16.2. The financial disruption of the manufacturing sector
   16.3. Impact of COVID-19 on emerging companies
   16.4. Significant mandates in the healthcare regulations initiated by administrations
   16.5. The overall economic slowdown of the developing and developed nations

17. FutureWise SME Key Takeaway Points for Client

Tables

Figures